440678-43-3

Basic information

• Product Name: L-Proline, 4-hydroxy-, ethyl ester, (4S)- (9CI)
• Synonyms: L-Proline, 4-hydroxy-, ethyl ester, (4S)- (9CI)
• CAS NO: 440678-43-3
• Molecular Formula: C₇H₁₃NO₃
• Molecular Weight: 159.18302
• Product Categories: ALCOHOL;CARBOXYLICESTER;PYRROLE;GLYCINESCAFFOLD
• Mol File: 440678-43-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 262.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.171±0.06 g/cm3(Predicted)
• PKA: 14.47±0.40(Predicted)
• CAS DataBase Reference: L-Proline, 4-hydroxy-, ethyl ester, (4S)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: L-Proline, 4-hydroxy-, ethyl ester, (4S)- (9CI)(440678-43-3)
• EPA Substance Registry System: L-Proline, 4-hydroxy-, ethyl ester, (4S)- (9CI)(440678-43-3)

Safety Data

• Hazardous Substances Data: 440678-43-3(Hazardous Substances Data)

Upstream product

• 142347-82-8 hydroxyproline ethyl ester hydrochloride 
• 627100-73-6 ethyl (2S,4S)-1-benzyl-4-hydroxypyrrolidine-2-carboxylate 
• 64-17-5 ethanol 
• 618-27-9 hydroxy L-proline 

Downstream Products

• 22029-01-2 cis-1-(N-benzyloxycarbonyl-glycyl)-4-hydroxy-L-proline 
• 618-27-9 hydroxy L-proline 
• 24587-32-4 cis-1-glycyl-4-hydroxy-L-proline 

Relevant articles and documents

INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS

The invention relates to proline derivatives and their salts, to pharmaceutical agents containing said derivatives and to the use of said agents for treating tumours. The invention also relates to methods for producing said compounds and pharmaceutical ag